<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01419847</url>
  </required_header>
  <id_info>
    <org_study_id>02082C (10856)</org_study_id>
    <nct_id>NCT01419847</nct_id>
  </id_info>
  <brief_title>Topical Penlac Nail Lacquer for Onychomycosis in Children</brief_title>
  <official_title>A Prospective, Double-blind, Placebo-controlled Trial of Topical Penlac Nail Lacquer for Therapy of Onychomycosis in Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rady Children's Hospital, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rady Children's Hospital, San Diego</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Five months of therapy is sufficient to treat onychomycosis in children. Topical therapy of
      onychomycosis in children with Penlac nail lacquer has comparable efficacy and a superior
      cost and safety profile compared to systemic therapy.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Therapeutic trials for the treatment of onychomycosis have been conducted in the adult
      population, but there is limited data available in the pediatric population.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2002</start_date>
  <completion_date type="Actual">May 2006</completion_date>
  <primary_completion_date type="Actual">December 2005</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mycological cure or global evaluation of 2 or less Mycological Cure</measure>
    <time_frame>Week 20</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Estimated cost of therapy</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Onychomycosis</condition>
  <arm_group>
    <arm_group_label>topical Penlac nail lacquer</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>3-1 randomization of active to placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ciclopirox</intervention_name>
    <arm_group_label>topical Penlac nail lacquer</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children between the ages of two and sixteen years

          -  Clinical diagnosis of toenail onychomycosis involving at least 20% of one nail plate

          -  Positive DTM reading or fungal culture for onychomycosis-either dermatophytes or
             non-dermatophyte mold

          -  Consent to participate in the study

          -  Women of child-bearing potential must have a negative urine pregnancy test at the
             baseline visit and be willing to practice effective contraception for the duration of
             the study.

        Exclusion Criteria:

          -  Children with allergy to Penlac or one of its ingredients

          -  Structural deformity of target nail plate

          -  Presence of active psoriasis or severe foot eczema

          -  Presence of immunodeficiency disorder

          -  Concurrent immune suppressive therapy or immune suppressive therapy within the last 3
             months

          -  Previous systemic antifungal therapy within the last 6 months

          -  Previous topical antifungal therapy within the last 14 days

          -  Female subjects who are pregnant, nursing mothers, those planning a pregnancy during
             the course of the study, or who become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>2 Years</minimum_age>
    <maximum_age>16 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sheila F Friedlander, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rady Children's Hospital, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Children's Hospital-San Diego</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2006</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 17, 2011</study_first_submitted>
  <study_first_submitted_qc>August 17, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 18, 2011</study_first_posted>
  <last_update_submitted>August 17, 2011</last_update_submitted>
  <last_update_submitted_qc>August 17, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 18, 2011</last_update_posted>
  <responsible_party>
    <name_title>Sheila F. Frieldander, MD; PI</name_title>
    <organization>Rady Children's Hopsital, San Diego</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Onychomycosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ciclopirox</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

